Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12971465 | 1.00 | DPP4 (0.39) | DPP4FFAR1MMEEIF4A3PTGS1 | |
| SCHEMBL743043 | 1.00 | DPP4 (0.39) | DPP4FFAR1MMEEIF4A3PTGS1 | |
| SCHEMBL743074 | 1.00 | DPP4 (0.39) | DPP4FFAR1MMEEIF4A3PTGS1 | |
| SCHEMBL12971168 | 0.81 | FFAR1 (0.40) | FFAR1MMEEIF4A3PTGS1PTGS2 | |
| SCHEMBL28650065 | 0.80 | DPP4 (0.34) | DPP4 | |
| SCHEMBL28048561 | 0.80 | FFAR1 (0.33) | DPP4FFAR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28304220 | 0.76 | DPP4 (0.33) | DPP4FFAR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3795621 | 0.74 | DPP4 (0.34) | DPP4FFAR1 | |
| SCHEMBL3453796 | 0.74 | DPP4 (0.37) | DPP4FFAR1 | |
| SCHEMBL28033444 | 0.73 | FFAR1 (0.38) | DPP4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846916-B2 | Sitagliptin synthesis | GENERICS [UK] LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-20120108598-A1 | SITAGLIPTIN SYNTHESIS | MYLAN INDIA PRIVATE LIMITED (IN) | 2012-05-03 | — | — | US | disclosed |
| EP-2430025-A1 | SITAGLIPTIN SYNTHESIS | Generics [UK] Limited (GB) | 2012-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108598-A1 | SITAGLIPTIN SYNTHESIS | DPP4, DPP7, DPP3 | DPP4 1/4885FFAR1 931/4885MME 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.